Hola,
Are you new here?

PID2022-143208OA-I00

financed

Cáncer

THERAPEUTIC RESISTANCE IS THE MAJOR OBSTACLE IN OUR AMBITION TO ERADICATE CANCER. RECENT INSIGHTS INTO THE MOLECULAR DETERMINANTS OF ACQUIRED TREATMENT RESISTANCE IN THE CLINICAL AND EXPERIMENTAL SETTING HAVE CHALLENGED THE WIDELY... see more

01/01/2022

FUNDACIO INSTITUT...

238K€

Project Budget: 238K€

Project leader

FUNDACIO INSTITUT D'INVESTIGACIO EN CIENCIES... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 12M€

PARTICIPATION DEPralty Sin fecha límite de participación.

Financing granted El organismo AGENCIA ESTATAL DE INVESTIGACIÓN notifico la concesión del proyecto The day 2022-01-01 We do not have the information of the call

0% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

FUNDACIO INSTITUT D'INVESTIG...

237.50K€ | Leader

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project leader

FUNDACIO INSTITUT D'INVESTIGACIO EN CIENCIES... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 12M€

Project Budget 238K€

participation deadline Sin fecha límite de participación.

Project description THERAPEUTIC RESISTANCE IS THE MAJOR OBSTACLE IN OUR AMBITION TO ERADICATE CANCER. RECENT INSIGHTS INTO THE MOLECULAR DETERMINANTS OF ACQUIRED TREATMENT RESISTANCE IN THE CLINICAL AND EXPERIMENTAL SETTING HAVE CHALLENGED THE WIDELY HELD VIEW OF SEQUENTIAL GENETIC EVOLUTION AS THE PRIMARY CAUSE OF DRUG RESISTANCE AND BROUGHT INTO SHARP FOCUS A RANGE OF NON-GENETIC ADAPTIVE MECHANISMS. NOTABLY, THE GENETIC COMPOSITION OF THE TUMOR AND THE NON-GENETIC MECHANISMS USED TO ESCAPE THERAPY ARE FREQUENTLY LINKED. REMARKABLY, ALTHOUGH SOME ONCOGENIC MUTATIONS ALLOW THE CANCER CELLS TO RAPIDLY REWIRE TRANSCRIPTIONALLY AND/OR METABOLICALLY TO SURVIVE IN THE PRESENCE OF A THERAPEUTIC INSULT, OTHER ONCOGENIC DRIVERS CONVEY AN INHERENT CELLULAR PLASTICITY TO THE CANCER CELL ENABLING LINEAGE SWITCHING AND/OR THE EVASION OF ANTICANCER IMMUNOSURVEILLANCE. THE ABUNDANCE OF NON-GENETIC MECHANISMS OF RESISTANCE POSES A NEW CHALLENGE TO THE FIELD THAT REQUIRES INNOVATIVE STRATEGIES TO MONITOR AND PREVENT THESE ADAPTIVE PROCESSES. THE ULTIMATE GOAL OF THIS PROPOSAL IS FOCUSED ON THE UNDERSTANDING OF THE NON-MUTATIONAL MECHANISM OF DRUG RESISTANCE IN MELANOMA USING SOPHISTICATED CANCER MODELS IN COMBINATION WITH SINGLE-CELL MULTIOMIC APPROACHES. IT WILL PAVE THE WAY TO NEW THERAPEUTIC AVENUES THAT MAY BE USED TO COMBAT THE NON-GENETIC ADAPTATION TO THERAPEUTIC PRESSURE INTRATUMOR HETEROGENEITY\SINGLE-CELL\DRUG RESISTANCE\NON-GENETIC\CANCER PLASTICITY

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers